Hypoglycemia, a dangerous drop in blood glucose levels related to insulin and sulfonylurea (SU) use, has been identified as one of the top three preventable adverse drug events by the U.S. Department of Health and Human Services. Yet the prevalence and high burden of disease in patients with type 2 diabetes (T2D), particularly the elderly, are often underappreciated in clinical settings. Supporting the early identification and management of those at greatest risk is critical.
The Endocrine Society has made reducing the incidence of hypoglycemia a priority for a number of years. The Hypoglycemia Prevention Initiative is a multi-year joint effort of the Endocrine Society and Avalere Health to determine best practices in primary care to reduce the impact of hypoglycemia on older (65+) people with type 2 diabetes (T2D) who use insulin and/or sulfonylurea, have a recent A1c <7%, and are at increased risk of hypoglycemia. To learn more, visit the Hypoglycemia Prevention Initiative page.
NOTICE: We are conducting a patient survey for those living with diabetes to discover gaps in their awareness of severe hypoglycemia, blood glucose management, and emergency glucagon. Please print and share our informational flyer about hypoglycemia and encourage your patients to participate by Monday, August 30.
From bench to bedside and all the stages in between, the Hormone Health Network is committed to supporting patient and public education.
Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.
Join our endocrine community and become a member! Only members receive access to a variety of member benefits that will enhance your career. If your membership has lapsed, rejoin today so that you can continue to receive your membership benefits.